Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System (2024)

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Very Positive)

Pulse Biosciences (NASDAQ: PLSE) ha anunciado el tratamiento exitoso de los primeros dos pacientes en un estudio de viabilidad en humanos utilizando su novedoso Cardiac Surgery System para la fibrilación auricular. El procedimiento, realizado en el Hospital St. Antonius en los Países Bajos, utilizó la tecnología patentada de la compañía, Nanosecond Pulsed Field Ablation™ (nsPFA™). El estudio incluirá hasta 30 pacientes y tiene como objetivo demostrar la seguridad, efectividad y durabilidad del dispositivo.

Puntos clave:

El sistema recibió la Designación de Dispositivo Innovador de la FDA en julio de 2024
Se inscribió recientemente en el Programa de Asesoramiento del Ciclo de Vida Completo del Producto de la FDA (TPLC)
Pulse Biosciences planea solicitar la aprobación previa a la comercialización (PMA) de la FDA
Se espera que un estudio clínico pivotal comience a principios de 2025

Pulse Biosciences (NASDAQ: PLSE)는 심방세동에 대한 혁신적인 Cardiac Surgery System을 사용한 최초의 인간 대상 타당성 연구에서 두 명의 환자에 대한 성공적인 치료를 발표했습니다. 네덜란드의 St. Antonius 병원에서 수행된 이 절차는 회사의 독점 기술인 Nanosecond Pulsed Field Ablation™ (nsPFA™) 기술을 활용했습니다. 이 연구는 최대 30명의 환자를 포함하며, 장치의 안전성, 효과성 및 내구성을 입증하는 것을 목표로 하고 있습니다.

주요 요점:

이 시스템은 2024년 7월 FDA 혁신 장치 지정(Breakthrough Device Designation)을 받았습니다.
최근 FDA의 전체 제품 생애 주기(TPLC) 자문 프로그램(TAP)에 등록되었습니다.
Pulse Biosciences는 상용화를 위한 FDA 사전 시장 승인(PMA)을 추진할 계획입니다.
중요한 임상 연구는 2025년 초에 시작될 것으로 예상됩니다.

Pulse Biosciences (NASDAQ: PLSE) a annoncé le traitement réussi des deux premiers patients dans une étude de faisabilité de première ligne sur l'homme utilisant son nouveau Cardiac Surgery System pour la fibrillation auriculaire. La procédure, réalisée à l'Hôpital St. Antonius aux Pays-Bas, a utilisé la technologie propriétaire de l'entreprise, Nanosecond Pulsed Field Ablation™ (nsPFA™). L'étude inclura jusqu'à 30 patients et vise à démontrer la sécurité, l'efficacité et la durabilité de l'appareil.

Points clés :

Le système a reçu la désignation de dispositif breakthrough de la FDA en juillet 2024
Il a récemment été inscrit au programme de consultation sur le cycle de vie complet du produit de la FDA (TPLC)
Pulse Biosciences prévoit de demander l'approbation pré-commercialisation (PMA) de la FDA pour la commercialisation
Une étude clinique critique devrait commencer au début de 2025

Pulse Biosciences (NASDAQ: PLSE) hat die erfolgreiche Behandlung der ersten beiden Patienten in einer ersten Machbarkeitsstudie am Menschen mit ihrem neuartigen Cardiac Surgery System zur Behandlung von Vorhofflimmern bekannt gegeben. Der Eingriff, der im St. Antonius Krankenhaus in den Niederlanden durchgeführt wurde, nutzte die hauseigene Technologie Nanosecond Pulsed Field Ablation™ (nsPFA™). Die Studie umfasst bis zu 30 Patienten und zielt darauf ab, die Sicherheit, Wirksamkeit und Haltbarkeit des Geräts nachzuweisen.

Wichtige Höhepunkte:

Das System erhielt im Juli 2024 die FDA Breakthrough Device Designation.
Es wurde kürzlich im FDA Total Product Life Cycle (TPLC) Beratung Programm (TAP) aufgenommen.
Pulse Biosciences plant, eine FDA-Vorabgenehmigung (PMA) zur Kommerzialisierung zu beantragen.
Eine entscheidende klinische Studie wird voraussichtlich Anfang 2025 beginnen.

Positive

Successful treatment of first two patients in first-in-human feasibility study
FDA Breakthrough Device Designation received in July 2024
Enrollment in FDA's prestigious TAP program
Planned submission for IDE approval to begin U.S. clinical work
Intention to begin pivotal clinical study in early 2025

Negative

None.

The successful treatment of the first two patients in Pulse Biosciences' first-in-human feasibility study for their Nano-PFA Cardiac Surgery System is a significant milestone. This study, involving up to 30 patients, aims to demonstrate the device's safety, effectiveness and durability for treating atrial fibrillation.

Key points to consider:

The system's ability to create rapid, controlled lesions in a fraction of the time compared to current thermal modalities is promising.
The non-thermal mechanism of nano-PFA potentially reduces the risk of collateral tissue damage.
The FDA Breakthrough Device Designation and enrollment in the TAP program indicate the technology's potential importance in public health.

While these initial results are encouraging, investors should note that this is still an early-stage study. The planned pivotal clinical study in early 2025 will be important for determining the technology's true potential and path to commercialization.

Pulse Biosciences' progress with its Nano-PFA Cardiac Surgery System could have significant financial implications:

The atrial fibrillation treatment market is substantial, with potential for rapid market penetration if the technology proves superior to current methods.
The FDA's Breakthrough Device Designation and TAP program enrollment could accelerate the regulatory process, potentially leading to earlier market entry.
If successful, this technology could become a new standard of care, driving revenue growth and market share gains.

However, investors should be cautious. The company still faces significant hurdles, including:

Completing larger clinical trials
Obtaining FDA approval
Commercialization challenges

These steps will require substantial time and capital investment before any potential return is realized. The company's financial stability and cash runway will be critical factors to monitor.

The Nano-PFA Cardiac Surgery System shows promising potential in addressing key challenges in atrial fibrillation treatment:

Speed: Creating lesions in 1/20th the time of current thermal technologies could significantly reduce procedure times and potentially improve outcomes.
Precision: The ability to create controlled, transmural lesions rapidly may enhance the procedure's effectiveness.
Safety: The non-thermal approach could reduce collateral tissue damage, a common concern with current ablation techniques.

However, the true test will be in the long-term results. The planned endocardial catheter-based remapping at three months post-treatment will be important in assessing the durability of the ablations. If successful, this technology could represent a significant advancement in surgical treatment of atrial fibrillation, potentially improving patient outcomes and reducing procedure times.

08/08/2024 - 08:00 AM

Company’s proprietary system used in study for patients with atrial fibrillation

Cardiac Surgery System enrolled in the FDA’s Total Product Life Cycle (TPLC) Advisory Program (TAP)*

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced treatment of the first two patients in the first-in-human feasibility study using its novel Cardiac Surgery System for the ablation of cardiac tissue for the treatment of atrial fibrillation.

Dr. Bart Van Putte, Cardiothoracic Surgeon at St. Antonius Hospital, used the Company’s Cardiac Surgery System to successfully treat two patients with atrial fibrillation at St. Antonius Hospital, Nieuwegein, The Netherlands. Dr. Van Putte was joined by colleagues and Pulse Biosciences’ Chief Medical Officer, Cardiac Surgery, Dr. Gan Dunnington and Chief Science Officer, Cardiac Surgery, Dr. Niv Ad during the concomitant procedure. The first-in-human feasibility study is a multicenter study of up to 30 patients that will include an endocardial catheter-based remapping to confirm chronic isolation at approximately three months post treatment.

“We are honored to partner with Pulse Biosciences and to be the first team to use this next-generation nano-PFA technology for the treatment of atrial fibrillation in cardiac surgery. The initial procedure results showed effective pulmonary vein and ‘box’ isolation with Pulse’s Cardiac Surgery System,” said Dr. Bart Van Putte, Cardiothoracic Surgeon at St. Antonius Hospital. “We were impressed by how rapidly and effectively we were able to produce linear ablations in a fraction of the time it takes with the current thermal modalities we use, such as radiofrequency or cryoablation.”

“These initial treatment results confirm our preclinical work with the cardiac surgical system. The patients tolerated our procedure well. We are pleased to see how the intuitive design of the device facilitates an efficient procedure where surgeons can create controlled lesions with adequate depth very rapidly,” added Dr. Gan Dunnington, Chief Medical Officer, Cardiac Surgery of Pulse Biosciences. “We are excited to continue enrollment in this feasibility clinical study, which is intended to demonstrate the device’s safety, effectiveness and durability profile.”

Pulse’s Cardiac Surgery System with Surgical Clamp is designed to produce durable, continuous, transmural, ablation lesions during cardiac surgery procedures for the treatment of atrial fibrillation. The bipolar clamp utilizes the Company’s proprietary nanosecond PFA technology. Based on pre-clinical studies, a single application of less than two seconds with the Surgical Clamp creates a consistent, transmural, durable ablation, which is significantly faster, requiring approximately one-twentieth the time of currently available thermal ablation technologies. Also, due to the non-thermal mechanism of action of nano-PFA, there is no risk of thermal spread that may cause undesired injury to collateral tissues, which compares favorably to thermal radiofrequency ablation.

The nano-PFA Cardiac Surgical System received FDA Breakthrough Device Designation in early July 2024. Recently the device was enrolled in the FDA’s TAP program. The FDA’s Center for Devices and Radiological Health (CDRH) launched the TAP program to help generate more rapid development of high-quality, safe, effective, and innovative medical devices that are critical to public health. TAP’s primary goal is to expedite patient access to innovative medical devices by providing early, frequent and strategic communications with the FDA and facilitating engagement with other key parties for developers of devices of public health importance. According to its website, the FDA has enrolled 46 devices in the TAP program to date, while there have been over 900 Breakthrough Device Designations granted.

“We continue to make great strides on the development of our current nano-PFA devices, three of which have now been used in patients with initial promising results. We are grateful for all the key opinion leader clinicians who have partnered with us to advance nano-PFA technology for the benefit of patients and clinicians worldwide,” stated President and Chief Executive Officer Burke T. Barrett. “These initial clinical results with the Cardiac Surgical System will inform the next steps of our clinical and regulatory strategy. We are excited to continue the momentum with the System following its Breakthrough Device Designation and recent enrollment into the prestigious TAP program. Moving forward, we intend to submit for IDE approval from the FDA to begin U.S. clinical work.”

The Company plans to pursue FDA premarket approval (PMA) to commercialize its nano-PFA Cardiac Surgical System in the United States as a treatment for atrial fibrillation. If granted by the FDA, a specific treatment indication would permit direct marketing of the device’s treatment benefits. The Company intends to begin its pivotal clinical study of its nano-PFA Cardiac Surgical System as a treatment for atrial fibrillation in early 2025 and will provide additional details on the study and its regulatory and commercial implications later this year.

*https://www.fda.gov/medical-devices/how-study-and-market-your-device/total-product-life-cycle-advisory-program-tap

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. Pulse Biosciences is now headquartered in Miami, Florida and maintains its office in Hayward, California.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the effectiveness of the Company’s CellFX nsPFA technology and CellFX System to create consistent, transmural, durable ablations in cardiac tissue in approximately one-twentieth the time of currently available thermal ablation technologies, statements concerning the Company’s expected product development efforts and future clinical studies and regulatory submissions and whether breakthrough designation or enrollment in the FDA’s TAP program can accelerate regulatory approval to market the Company’s Cardiac Surgery System in the United States, statements concerning whether any clinical study will show that the Company’s novel nsPFA mechanism of action will deliver fast and precise ablations in cardiac tissue, statements concerning early clinical successes and whether they are predictive of the safety and efficacy of any medical device such as the CellFX nsPFA Cardiac Surgery System, and Pulse Biosciences’ expectations, whether stated or implied, regarding whether the Company’s CellFX nsPFA technology will become a disruptive, superior and durable treatment option for treating atrial fibrillation or any other medical condition, and other future events. These statements are not historical facts but rather are based on Pulse Biosciences’ current expectations, estimates, and projections regarding Pulse Biosciences’ business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences’ control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences’ filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circ*mstances in the future, even if new information becomes available.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240805012633/en/

Investors:
Pulse Biosciences, Inc.
Burke T. Barrett, President and CEO
IR@pulsebiosciences.com

Gilmartin Group
Philip Trip Taylor
415.937.5406
philip@gilmartinir.com

Source: Pulse Biosciences, Inc.

FAQ

What is Pulse Biosciences' Cardiac Surgery System designed for?

Pulse Biosciences' Cardiac Surgery System is designed to produce durable, continuous, transmural ablation lesions during cardiac surgery procedures for the treatment of atrial fibrillation using nanosecond Pulsed Field Ablation (nsPFA) technology.

How many patients will be included in the first-in-human feasibility study for PLSE's Cardiac Surgery System?

The first-in-human feasibility study for Pulse Biosciences' (PLSE) Cardiac Surgery System will include up to 30 patients across multiple centers.

When did Pulse Biosciences (PLSE) receive FDA Breakthrough Device Designation for its Cardiac Surgery System?

Pulse Biosciences (PLSE) received FDA Breakthrough Device Designation for its nano-PFA Cardiac Surgical System in early July 2024.

When does Pulse Biosciences (PLSE) plan to begin its pivotal clinical study for the Cardiac Surgery System?

Pulse Biosciences (PLSE) intends to begin its pivotal clinical study of the nano-PFA Cardiac Surgical System as a treatment for atrial fibrillation in early 2025.